AC Immune SA (ACIU) News
Filter ACIU News Items
ACIU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACIU News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ACIU News From Around the Web
Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.
US Penny Stocks Spotlight: AC Immune And Two Others To ConsiderAs the U.S. equities market starts the new year with a continued slump, investors are closely monitoring opportunities that might emerge amidst broader market challenges. Penny stocks, often representing smaller or newer companies, remain an intriguing niche for those seeking growth potential beyond the well-trodden paths of large-cap investments. Despite their vintage name, these stocks can still offer surprising value and stability when backed by solid financial foundations. |
High Growth Tech Stocks in the United StatesOver the last 7 days, the United States market has dropped 2.6%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of fluctuating performance and anticipated growth, identifying high growth tech stocks involves looking at companies with innovative technologies and strong potential for future expansion. |
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2AC Immune (ACIU) SA announced interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome, DS. Targeting toxic forms of amyloid beta, ACI-24.060 is an active immunotherapy covering Abeta 1-15. The interim analysis was based on data from the first two cohorts of individuals with DS receiving low-dose and mid-dose ACI-24.060. DS subjects in the interim analysis have been treated for up to one year, with no serious adverse events relat |
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo cases of amyloid-related imaging abnormalities observed in this study populationBased upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome Lausanne, Switzerland, December 10, 2024 – AC Immune SA (NASDAQ: A |
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefitAC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease vaccine like therapy. |
AC Immune reports interim results from Phase 2 trial of ACI-7104.056AC Immune (ACIU) announced positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein active immunotherapy candidate, for the treatment of patients with early Parkinson’s disease. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are encouraged by these initial Phase 2 safety and immunogenicity data on our ACI-7104.056 active immunotherapy being studied in early Parkinson’s disease. The level of immu |
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseAC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations100% of patients receiving ACI-7104.056 responded against the target antigenACI-7104.056 is well tolerated with no clinically relevant safety issues reported to date Lausanne, Switzerland, November 14, 2024 – AC Immune SA (NASD |
AC Immune to Present at the Jefferies 2024 London Healthcare ConferenceAC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024. The fireside chat will take |
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New EstimatesIt's been a good week for AC Immune SA ( NASDAQ:ACIU ) shareholders, because the company has just released its latest... |
AC Immune: Q3 Earnings SnapshotLAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Tuesday reported third-quarter net income of $6.4 million, after reporting a loss in the same period a year earlier. The Lausanne, Switzerland-based company said it had net income of 6 cents per share. The results topped Wall Street expectations. |